Welcome to our dedicated page for Arcutis Biotherapeutics SEC filings (Ticker: ARQT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Arcutis Biotherapeutics filings document regulatory disclosures for a Nasdaq-listed commercial-stage biopharmaceutical company developing and commercializing dermatology treatments. Its Form 8-K reports furnish quarterly and annual financial-results releases, business updates, ZORYVE product-revenue commentary, clinical and regulatory program updates, and securities information for its common stock listed on the Nasdaq Global Select Market.
Arcutis proxy and governance filings cover annual meeting matters, executive compensation, equity awards, board composition, and shareholder voting items. Other material-event disclosures address director changes, compensatory arrangements, consulting or transition agreements, and related governance matters within the company’s public-company reporting framework.
Masaru Matsuda filed a notice to sell 40,638 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on NASDAQ, with an approximate sale date of 02/02/2026. The aggregate market value of the planned sale is 1,027,275 based on the filing data, versus 122,492,192 common shares outstanding.
The shares to be sold were acquired through restricted stock vesting from Arcutis Biotherapeutics on multiple dates, including 02/01/2026, 02/01/2025, 11/18/2024, 11/01/2024, and 08/01/2024, in amounts that total 40,638 shares. In the past three months, Matsuda also sold 1,675 shares on 12/01/2025 for gross proceeds of 50,041 and 2,550 shares on 11/19/2025 for gross proceeds of 72,056.
Arcutis Biotherapeutics insider Todd Edwards filed a notice to sell 2,052 shares of common stock under Rule 144. The planned sale, through Merrill on NASDAQ, has an aggregate market value of $52,322.72 and an approximate sale date of February 2, 2026.
The shares to be sold were acquired as restricted stock that vested on February 1, 2026 from Arcutis Biotherapeutics Inc. The filing also reports that Edwards sold 29,131 common shares on November 6, 2025 for gross proceeds of $732,051.95 during the prior three months.
A shareholder of Arcutis Biotherapeutics plans to sell 1,320 common shares under Rule 144. The shares have an aggregate market value of $33,657.89, with Arcutis having 122,492,192 shares outstanding. The sale, through Merrill Lynch on NASDAQ, is expected around February 2, 2026.
The seller acquired the 1,320 shares on February 1, 2026 via restricted stock vesting from Arcutis Biotherapeutics, with payment on the same date. Over the prior three months, the same person sold 88 common shares on November 3, 2025 for gross proceeds of $2,155.
Arcutis Biotherapeutics insider schedules sale of restricted shares under Rule 144. A holder has filed to sell 3,675 shares of Arcutis Biotherapeutics common stock through Merrill Lynch on or about 02/02/2026 on the NASDAQ, with an aggregate market value listed at $93,706.62.
These shares were acquired on 02/01/2026 via restricted stock vesting from Arcutis Biotherapeutics. The notice also lists several prior sales of Arcutis common stock by Patrick Burnett during the past three months, each with specified dates, share amounts, and gross proceeds.
Arcutis Biotherapeutics insider activity: A holder has filed to sell 19,833 shares of Arcutis Biotherapeutics common stock under Rule 144 through Merrill on the NASDAQ, with an approximate sale date of 02/02/2026. The filing notes 122,492,192 common shares outstanding for this class.
The 19,833 shares were acquired on 02/01/2026 via a restricted stock vest from Arcutis Biotherapeutics, Inc., with payment also dated 02/01/2026. In the prior three months, Todd F. Watanabe reported sales of 48,945 and 1,055 common shares, with gross proceeds of 1,485,759 and 31,650, respectively.
Arcutis Biotherapeutics insider Howard Welgus filed a Rule 144 notice to sell 10,000 shares of common stock through Merrill, with an aggregate market value of $250,482.69. The shares relate to a stock option exercise on 06/04/2018, paid in cash.
Welgus reports prior sales over the past three months of 10,000 shares each on 11/03/2025, 12/01/2025, and 01/02/2026, with gross proceeds of $252,668.51, $302,133.02, and $289,606.03. The planned sale is expected around 02/02/2026 on NASDAQ, where 122,492,192 shares of the issuer’s common stock are outstanding.
Jennison Associates LLC reports beneficial ownership of 6,758,006 shares of Arcutis Biotherapeutics Inc. common stock, representing 5.5% of the outstanding class as of 12/31/2025. Jennison has sole power to vote these shares and shared power to dispose of them.
The firm states the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Arcutis. The filing is signed by a Senior Vice President, Compliance, on behalf of Jennison Associates LLC.
Arcutis Biotherapeutics, Inc. Executive Vice President and Chief Medical Officer Patrick Burnett reported a planned sale of company stock. On January 5, 2026, he sold 2,490 shares of Arcutis common stock at a weighted average price of $28.9822 per share under a Rule 10b5-1 trading plan adopted on December 12, 2024, with a plan end date of February 27, 2026. After this transaction, he beneficially owned 94,120 shares of Arcutis common stock directly.
Arcutis Biotherapeutics, Inc. director Howard G. Welgus reported selling 10,000 shares of common stock on 01/02/2026 at a weighted average price of $28.9606 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 11, 2025, with a plan end date of May 29, 2026.
After this planned sale, Welgus beneficially owned 69,744 shares of Arcutis common stock directly. The shares were sold in multiple transactions at prices ranging from $28.905 to $29.17 per share.
Arcutis Biotherapeutics Executive Vice President and Chief Medical Officer Patrick Burnett reported an option exercise and share sale in Arcutis Biotherapeutics, Inc. common stock. On 12/15/2025, he exercised a stock option for 11,500 shares at an exercise price of $3.64 per share, then sold 11,500 shares on the same date at a weighted average price of $28.9436 per share under transaction code S.
These trades were made pursuant to a Rule 10b5-1 trading plan adopted on 12/12/2024, with a plan end date of 02/27/2026. After the transactions, Burnett beneficially owned 98,307 shares of common stock directly and 143,750 stock options. The report also corrects a prior overstatement of his beneficial ownership by 18 shares due to a scrivener's error.